A clinical study to evaluate Symbicort Turbuhaler used ’as needed’ in adults and adolescents with asthma - SYGMA2

Inclusion Criteria

• 1.Provision of informed consent prior to any study specific procedures. For patients under-age, signed informed consent from both the patient and the patient's parent/legal guardian is required
• 2.Male or Female, ≥12 years of age
• 3.Documented diagnosis of asthma for at least 6 months prior to Visit 1
• 4.Patients who are in need of GINA step 2 treatment
• 5.Patients treated with a short acting inhaled bronchodilator(s) only should have pre-bronchodilator FEV1 ≥ 60 % of predicted normal (PN) and post-bronchodilator FEV1 ≥ 80 % PN
• 6.Patients treated with low stable dose of ICS or leukotriene antagonists in addition to short acting inhaled bronchodilator(s) should have pre-bronchodilator FEV1 ≥80 % PN
• 7.Patients should have reversible airway obstruction
• 8.To be randomized patients must have used Bricanyl Turbuhaler as needed on at least 3 separate days during the last week of the run in period